NKTR shows a dramatic 85% reduction in outstanding shares (from 186M to 29M shares) alongside severe cash burn and deteriorating operations despite doubled revenue.
The massive share reduction suggests a significant corporate restructuring event such as a reverse stock split, while the company burned through 66% of its cash reserves despite revenue doubling. The combination of operational losses widening and critical dependence on Eli Lilly's cooperation for key drug development creates substantial execution risk for investors.
Revenue doubled to $308M but gross profit collapsed 76% to just $623K, indicating severely deteriorated margins, while net losses widened 38% to $164M and operating cash flow deteriorated to -$209M. Cash reserves plummeted 66% to only $15M while stockholders' equity paradoxically increased 48% to $90M, likely due to the dramatic share count reduction. The overall picture signals a company struggling with profitability and cash management despite top-line growth, creating immediate liquidity concerns.
Strong top-line growth of 101.2% — accelerating demand or successful expansion into new markets.
Capex reduced 88.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Cash declined 65.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Equity base grew 47.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Net income declined 37.9% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Liabilities reduced 21.6% — deleveraging improves balance sheet strength and financial flexibility.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
Current liabilities reduced — improved short-term financial position and working capital health.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →